Cardiology Research Dubrava Prospective Registry

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A nyilvántartás olyan felnőtteket keres, akiket egy központban kezelnek szívritmus-eszközzel, vénás vérrögképződéssel, akut koszorúér-szindrómával vagy TAVI szívbillentyűvel.

Életkor

18 éves vagy idősebb

Nem

Minden nem

A részvétel fő kizáró okai

• Az előírások be nem tartása
• Nem jár kontrollra ebben a központban

A regiszter feltételei, szó szerint

Mit akar kideríteni a vizsgálat

Cardiology Research Dubrava registry is a prospective, single centre registry including patients with acute coronary syndrome with and without ST segment elevation, patients with heart failure who were prescribed with SGLT-2 inhibitors, patients implanted with TAVI, patients with venous thromboembolism, patients with pulmonary embolism who underwent thromboaspiration procedure, patients implanted with ICD, CRT and conduction system pacing devices, as well as patients with atrial fibrillation who underwent pulmonary vein isolation and are prescribed with long-term anticoagulation therapy.

A vizsgálat 6 csoportja

• Acute coronary syndrome - ACS

  patients who were diagnosed with acute coronary syndrome: STEMI, non-STE ACS - NSTEMI and unstable angina, who underwent coronary angiography and were prescribed with optimal medicament therapy

  Kezelés: SGLT-2 inh therapy, CIED implantation, thromboaspiration,

• Transcatheter aortic valve implantation - TAVI

  patients with aortic stenosis who underwent transcatheter percotaneous implantation of the arteficial aortic valve

  Kezelés: SGLT-2 inh therapy, CIED implantation, thromboaspiration,

• Venous thromboembolism - VTE

  patients with pulmonary embolism and deep vein thrombosis, with a focus on those who underwent thromboaspiration due to high or medium-high risk pulmonary embolism

  Kezelés: SGLT-2 inh therapy, CIED implantation, thromboaspiration,

• Heart failure with SGLT2 inhibitor therapy included - HF-SGLT2

  patients with heart failure with reduced, mid-reduced and preserved systolic function who were prescribed with a SGLT-2 inhibitor therapy, and other optimal medicament therapy for HF

  Kezelés: SGLT-2 inh therapy, CIED implantation, thromboaspiration,

• Cardiac implantable electronic device - CIED

  patients who were implanted with a cardiac implantable electronic device: pacemaker, conduction system pacing device, cardioverter-defibrilator or cardiac resynchronization therapy with or without defibrilator option

  Kezelés: SGLT-2 inh therapy, CIED implantation, thromboaspiration,

• Arrhythmias

  patients who underwent electrophysiology study, including PVI for atrial fibrillation, as well as SVT ablations, and ventricular arrhythmia ablation (both premature ventriclar beats and ventricular tachycardia ablation in ischsmic and non-ischemic cardiomyopathy).